The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ESH AL 2020 | Immunotherapy for pediatric AML
Sarah Tasian, MD, Children’s Hospital of Philadelphia, Philadelphia, PA, outlines the current immunotherapeutic landscape with a focus on ongoing clinical trials for pediatric patients with acute myeloid leukemia (AML). Specifically, bispecific T-cell-engaging antibodies, natural killer (NK) cells and CAR-T cells are discussed. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
